Merit Medical Acquires Biolife Delaware for $120 Million

The latest announcement is out from Merit Medical Systems ( (MMSI) ).

On May 20, 2025, Merit Medical Systems acquired Biolife Delaware, L.L.C., a manufacturer of hemostatic devices, for approximately $120 million. This strategic acquisition is expected to enhance Merit’s product portfolio and contribute to its revenue growth, with projections of adding $18 million annually starting in 2026. The acquisition aligns with Merit’s goal of improving profitability and expanding its market reach, although it is anticipated to be slightly dilutive to the company’s 2025 financial performance due to transaction-related expenses.

The most recent analyst rating on (MMSI) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Merit Medical Systems stock, see the MMSI Stock Forecast page.

Spark’s Take on MMSI Stock

According to Spark, TipRanks’ AI Analyst, MMSI is a Outperform.

Merit Medical Systems is performing well financially with strong revenue growth and operational efficiency. However, valuation concerns and macroeconomic challenges such as tariffs pose risks. The technical analysis suggests caution with resistance levels approaching, while recent corporate events and earnings calls provide a balanced yet optimistic outlook.

To see Spark’s full report on MMSI stock, click here.

More about Merit Medical Systems

Merit Medical Systems, Inc. is a global leader in healthcare technology, specializing in products that support a wide range of medical procedures. The company focuses on providing solutions for cardiovascular and endoscopy segments, aiming to standardize and simplify post-procedure care.

Average Trading Volume: 780,609

Technical Sentiment Signal: Buy

Current Market Cap: $5.8B

For a thorough assessment of MMSI stock, go to TipRanks’ Stock Analysis page.